Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy

Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy

Prime-boost vaccination employing heterologous viral vectors encoding an antigen is an effective strategy to maximize the antigen-specific immune response. Replication-deficient adenovirus serotype 5 (Ad5) is currently being evaluated clinically in North America as a prime in conjunction with oncoly...

Full description

Bibliographic Details
Main Authors: Fanny Tzelepis, Harsimrat Kaur Birdi, Anna Jirovec, Silvia Boscardin, Christiano Tanese de Souza, Mohsen Hooshyar, Andrew Chen, Keara Sutherland, Robin J. Parks, Joel Werier, Jean-Simon Diallo
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Molecular Therapy: Oncolytics
Subjects:
anti-DEC205
rhabdovirus
oncolytic vaccine
Ad5
prime-boost
immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2372770520301583

Internet

http://www.sciencedirect.com/science/article/pii/S2372770520301583

Similar Items